Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis

被引：0

作者：

Pietro Lampertico

Stefan Mauss

Marcello Persico

Stephen T. Barclay

Steven Marx

Kristina Lohmann

Mark Bondin

ZhenZhen Zhang

Fiona Marra

Pamela S. Belperio

Heiner Wedemeyer

Steven Flamm

机构：

[1] Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico,Division of Gastroenterology and Hepatolgy, CRC “A.M. and A.Migliavacca” Center for Liver Disease

[2] University of Milan,Department of Pathophysiology and Transplantation

[3] Center for HIV and Hepatogastroenterology,Internal Medicine and Hepatology Unit

[4] University of Salerno,Department of Life Sciences

[5] Glasgow Caledonian University,Department of Veterans Affairs

[6] Gastroenterology,Department of Gastroenterology and Hepatology

[7] Glasgow Royal Infirmary,Department of Gastroenterology, Hepatology and Endocrinology

[8] AbbVie Inc.,undefined

[9] AbbVie Deutschland GmBH Co. KG,undefined

[10] University of Liverpool Hepatology Drug Interactions Group,undefined

[11] VA Palo Alto Healthcare System,undefined

[12] Essen University Hospital,undefined

[13] Leberstiftungs-GmbH Deutschland,undefined

[14] Hannover Medical School,undefined

[15] Northwestern University Feinberg School of Medicine,undefined

来源：

Advances in Therapy | 2020年 / 37卷

关键词：

Fibrosis; Hepatitis C; Infectious disease; Review; Therapeutics;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：4033 / 4042

页数：9

共 50 条

[1] Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis
Pietro Lampertico
Stefan Mauss
Marcello Persico
Stephen T. Barclay
Steven Marx
Kristina Lohmann
Mark Bondin
ZhenZhen Zhang
Fiona Marra
Pamela S. Belperio
Heiner Wedemeyer
Steven Flamm
Advances in Therapy, 2020, 37 : 4755 - 4756
[2] Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve, Compensated Cirrhotic HCV Patients
Nancy Reau
Wei-Han Cheng
Qiujun Shao
Steven E. Marx
Hannah Brooks
Anthony Martinez
Infectious Diseases and Therapy, 2023, 12 : 1849 - 1860
[3] Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naive Patients with Compensated Cirrhosis
Lampertico, Pietro
Mauss, Stefan
Persico, Marcello
Barclay, Stephen T.
Marx, Steven
Lohmann, Kristina
Bondin, Mark
Zhang, ZhenZhen
Marra, Fiona
Belperio, Pamela S.
Wedemeyer, Heiner
Flamm, Steven
ADVANCES IN THERAPY, 2020, 37 (09) : 4033 - 4042
[4] Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry
Te-Sheng Chang
Chung-Feng Huang
Hsing-Tao Kuo
Ching-Chu Lo
Chien-Wei Huang
Lee-Won Chong
Pin-Nan Cheng
Ming-Lun Yeh
Cheng-Yuan Peng
Chien-Yu Cheng
Jee-Fu Huang
Ming-Jong Bair
Chih-Lang Lin
Chi-Chieh Yang
Szu-Jen Wang
Tsai-Yuan Hsieh
Tzong-Hsi Lee
Pei-Lun Lee
Wen-Chih Wu
Chih-Lin Lin
Wei-Wen Su
Sheng-Shun Yang
Chia-Chi Wang
Jui-Ting Hu
Lein-Ray Mo
Chun-Ting Chen
Yi-Hsiang Huang
Chun-Chao Chang
Chia-Sheng Huang
Guei-Ying Chen
Chien-Neng Kao
Chi-Ming Tai
Chun-Jen Liu
Mei-Hsuan Lee
Pei-Chien Tsai
Chia-Yen Dai
Jia-Horng Kao
Han-Chieh Lin
Wang-Long Chuang
Chi-Yi Chen
Kuo-Chih Tseng
Chao-Hung Hung
Ming-Lung Yu
Hepatology International, 2023, 17 : 550 - 561
[5] Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection
Steven L. Flamm
Jens Kort
Steven E. Marx
John Strezewski
Douglas E. Dylla
Bruce Bacon
Michael P. Curry
Naoky Tsai
Nicole Wick
Advances in Therapy, 2020, 37 : 2267 - 2274
[6] Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naive Patients with Compensated Cirrhosis (vol 37, pg 4033, 2020)
Lampertico, Pietro
Mauss, Stefan
Persico, Marcello
Barclay, Stephen T.
Marx, Steven
Lohmann, Kristina
Bondin, Mark
Zhang, ZhenZhen
Marra, Fiona
Belperio, Pamela S.
Wedemeyer, Heiner
Flamm, Steven
ADVANCES IN THERAPY, 2020, 37 (11) : 4755 - 4756
[7] Real-World Efficacy and Safety of Universal 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve Patients from a Nationwide HCV Registry in Taiwan
Yang, Chun-Chi
Huang, Chung-Feng
Chang, Te-Sheng
Lo, Ching-Chu
Hung, Chao-Hung
Huang, Chien-Wei
Chong, Lee-Won
Cheng, Pin-Nan
Yeh, Ming-Lun
Peng, Cheng-Yuan
Cheng, Chien-Yu
Huang, Jee-Fu
Bair, Ming-Jong
Lin, Chih-Lang
Yang, Chi-Chieh
Wang, Szu-Jen
Hsieh, Tsai-Yuan
Lee, Tzong-Hsi
Lee, Pei-Lun
Wu, Wen-Chih
Lin, Chih-Lin
Su, Wei-Wen
Yang, Sheng-Shun
Wang, Chia-Chi
Hu, Jui-Ting
Mo, Lein-Ray
Chen, Chun-Ting
Huang, Yi-Hsiang
Chang, Chun-Chao
Huang, Chia-Sheng
Chen, Guei-Ying
Kao, Chien-Neng
Tai, Chi-Ming
Liu, Chun-Jen
Lee, Mei-Hsuan
Kuo, Hsing-Tao
Tsai, Pei-Chien
Dai, Chia-Yen
Kao, Jia-Horng
Lin, Han-Chieh
Chuang, Wang-Long
Tseng, Kuo-Chih
Chen, Chi-Yi
Yu, Ming-Lung
INFECTIOUS DISEASES AND THERAPY, 2024, 13 (06) : 1199 - 1213
[8] Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naive, Compensated Cirrhotic HCV Patients
Reau, Nancy
Cheng, Wei-Han
Shao, Qiujun
Marx, Steven E.
Brooks, Hannah
Martinez, Anthony
INFECTIOUS DISEASES AND THERAPY, 2023, 12 (07) : 1849 - 1860
[9] Updated Results from the Retrospective CREST Study on the Safety and Effectiveness of 8-Week Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis
Cornberg, Markus
Hueppe, Dietrich
Sarrazin, Christoph
Ahumada, Adriana
Plaza, Francisco Jorquera
Marino, Zoe
Otano, Juan Isidro Uriz
Conway, Brian
Myles, Lindsay
Ramji, Alnoor
Abergel, Armand
Asselah, Tarik
Larrey, Dominique
Aghemo, Alessio
Andreoni, Massimo
Gasbarrini, Antonio
Lampertico, Pietro
Persico, Marcello
Villa, Erica
Carmiel, Michal
Chodick, Gabriel
Weil, Clara
Bhagat, Abhi
Bondin, Mark
Butrymowicz, Isabel
Song, Yanna
Semizarov, Dimitri
Sonparote, Sadhana
Llamas, Cynthia
ADVANCES IN THERAPY, 2024, 41 (12) : 4669 - 4682
[10] Real-World Safety and Effectiveness of an 8-Week Regimen of Glecaprevir/Pibrentasvir in Patients with Hepatitis C and Cirrhosis
Lu, Mei
Rupp, Loralee B.
Melkonian, Christina
Trudeau, Sheri
Daida, Yihe G.
Schmidt, Mark A.
Gordon, Stuart C.
ADVANCES IN THERAPY, 2024, 41 (02) : 744 - 758

← 1 2 3 4 5 →